Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 3/20 | 0.51 |
| ▸ | CYP19A1 known ✓ | P11511 | 2/20 | 0.45 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.43 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.43 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.43 |
| ▸ | CCR5 known ✓ | P51681 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6873428 | 0.99 | MAOB (0.53) | MAOBKDM4ECYP19A1CYP11B1CYP11B2 | |
| SCHEMBL2573943 | 0.84 | MAOB (0.51) | MAOBCYP19A1CYP11B1CYP11B2MRGPRX4 | |
| SCHEMBL3490042 | 0.80 | MAOB (0.57) | MAOBKDM4EMRGPRX4HPGDSMN1; SMN2 | |
| SCHEMBL6766128 | 0.80 | MAOB (0.57) | MAOBKDM4EMRGPRX4HPGDSMN1; SMN2 | |
| SCHEMBL1680776 | 0.80 | MAOB (0.53) | MAOBKDM4ECYP19A1CYP11B1CYP11B2 | |
| SCHEMBL6477064 | 0.79 | MAOB (0.55) | MAOBCYP19A1CYP11B1CYP11B2MRGPRX4 | |
| SCHEMBL6212565 | 0.79 | MAOB (0.55) | MAOBMRGPRX4PTGER1GABRG2GABRB3 | |
| SCHEMBL7141620 | 0.79 | KDM4E (0.69) | KDM4EHPGDSMN1; SMN2HTR1AADRA1D | |
| SCHEMBL7129137 | 0.79 | MAOB (0.58) | MAOBKDM4EMRGPRX4SMN1; SMN2PTGER1 | |
| SCHEMBL1060980 | 0.79 | MAOB (0.58) | MAOBMRGPRX4PTGER1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812231-B2 | INHIBITING ACTIVATED BLOOD-COAGULATION FACTOR X | AJINOMOTO CO., INC. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20020107290-A1 | Benzamidine derivative | AJINOMOTO CO., INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-6410538-B2 | ANTICOAGULANT OR AN AGENT FOR TREATING OR PREVENTING THROMBI OR EMBOLI | AJINOMOTO CO., INC. (JP) | 2002-06-25 | — | — | US | disclosed |
| US-20010056123-A1 | Anticoagulant or an agent for treating or preventing thrombi or emboli | AJINOMOTO CO., INC (JP) | 2001-12-27 | — | — | US | disclosed |
| CN-1311771-A | Benzamidine derivative | AJINOMOTO KK (JP) | 2001-09-05 | — | — | CN | disclosed |
| EP-1086946-A1 | BENZAMIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2001-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107290-A1 | Benzamidine derivative | SERPINE1, SERPINC1, TFPI | MAOB 377/4885CYP19A1 1405/4885GABRG2 1625/4885 |
| US-20010056123-A1 | Anticoagulant or an agent for treating or preventing thrombi or emboli | SERPINC1, SERPINE1, F2 | MAOB 478/4885CYP19A1 1708/4885GABRG2 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.